Wednesday, July 8, 2026

pharma · Chronic Spontaneous Urticaria (CSU) · Asthma · SPRY

Ars Pharmaceuticals Irl

Ars Pharmaceuticals Irl clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
187 Employees
Public company Type
SPRY · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Employees
187
Programs
8
Drugs
7
Patents
0
Intelligence · Clinical Programs

Ars Pharmaceuticals Irl projects

4 ClinicalTrials.gov programs sponsored by Ars Pharmaceuticals Irl.

Ars Pharmaceuticals Irl has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ARS-1

    Ars Pharmaceuticals Irl Limited

    Asthma

    phase 2 small molecule completed

    1 trial
  2. ARS-1

    Ars Pharmaceuticals Irl Limited

    Urticaria

    phase 2 small molecule completed

    1 trial
  3. EPI-U02

    Ars Pharmaceuticals Irl Limited

    Chronic Spontaneous Urticaria (CSU)

    phase 2 small molecule active

    1 trial
  4. Placebo

    Ars Pharmaceuticals Irl Limited

    Urticaria Chronic

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Ars Pharmaceuticals Irl have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.